Results 151 to 160 of about 25,164 (313)

Real-world evaluation of change in depressive symptoms among patients with treatment-resistant depression treated with esketamine. [PDF]

BMC Psychiatry
Marci CD, Joshi K, Severtson SG, Breeze JL, Jha MK.   +4 more
europepmc   +1 more source

Two Cases of Decreased 123I-Metaiodobenzylguanidine Lung Uptake in Metaiodobenzylguanidine Scintigraphy While Taking Selective Serotonin Reuptake Inhibitor/Serotonin Noradrenaline Reuptake Inhibitor

, 2020
Shinobu Adaniya, M. Takahashi, Keitaro Koyama, Kenichiro Ogane, Toshimitsu Momose   +4 more
openalex   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Safety of Vortioxetine in Patients With Depression: A Post-Marketing Surveillance Study of Intracranial Hemorrhage in a Japanese Health Insurance Claims Database. [PDF]

Neuropsychopharmacol Rep
Inoue T, Otake R, Hoshino T.
europepmc   +1 more source

Selective Serotonin Re-uptake Inhibitors: An overview.

Psychiatria Danubina, 2018
Selective serotonin re-uptake inhibitors (SSRIs) are front-line pharmacotherapies in the treatment of major depressive disorder (MDD), a disorder characterized by a persistent low mood, anhedonia and feelings of worthlessness. Since their formulation over 40 years ago, there have been several conflicting studies exploring the efficacy of these highly ...
openaire   +2 more sources

Neurochemical Profile of Lu 19‐005, a Potent Inhibitor of Uptake of Dopamine, Noradrenaline, and Serotonin

, 1985
John Hyttel, Jens‐Jørgen Larsen
openalex   +1 more source

Rare but relevant: Ibogaine and cardiovascular complications—prolonged QT interval and ventricular arrhythmias

Addiction, EarlyView.
Abstract Revived interest in psychedelic‐assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti‐addictive potential. Evidence from observational, open‐label, and limited randomized placebo‐controlled trials indicates that ibogaine and its metabolite noribogaine reduce craving and withdrawal symptoms in ...
Tibor Markus Brunt
wiley   +1 more source

A Case Series of Neuropsychological Outcome After Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Refractory Obsessive–Compulsive Disorder

, 2021
Neuromodulation: Technology at the Neural Interface, EarlyView.
Tim A. M. Bouwens van der Vlis, Annelien A. Duits   +1 more
wiley   +1 more source

Putative new biomarkers for renal transporter-mediated drug-drug interactions: Characterization as substrates of organic cation transporter 2, multidrug and toxin extrusion protein 1, and other important drug transporters. [PDF]

Drug Metab Dispos
Gessner A, Picurová J, Englhard L, Müller F, Fromm MF, König J.   +5 more
europepmc   +1 more source

Antinociceptive Interactions between Mu-Opioid Receptor Agonists and the Serotonin Uptake Inhibitor Clomipramine in Rhesus Monkeys: Role of Mu Agonist Efficacy [PDF]

, 2010
Matthew L. Banks, Kenner C. Rice, S. Stevens Negus   +2 more
openalex   +1 more source